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Rodent modelIn human trials certain heat shock protein 90 (Hsp90) inhibitors, including 17-DMAG and NVP-AUY922, have
caused visual disorders indicative of retinal dysfunction; others such as 17-AAG and ganetespib have not. To
understand these safety proﬁle differences we evaluated histopathological changes and exposure proﬁles of
four Hsp90 inhibitors, with or without clinical reports of adverse ocular effects, using a rat retinal model. Retinal
morphology, Hsp70 expression (a surrogate marker of Hsp90 inhibition), apoptotic induction and pharmacoki-
netic drug exposure analysis were examined in rats treated with the ansamycins 17-DMAG and 17-AAG, or with
the second-generation compounds NVP-AUY922 and ganetespib. Both 17-DMAG and NVP-AUY922 induced
strong yet restricted retinal Hsp70 up-regulation and promoted marked photoreceptor cell death 24 h after
the ﬁnal dose. In contrast, neither 17-AAG nor ganetespib elicited photoreceptor injury. When the relationship
between drug distribution and photoreceptor degenerationwas examined, 17-DMAG and NVP-AUY922 showed
substantial retinal accumulation, with high retina/plasma (R/P) ratios and slow elimination rates, such that 51%
of 17-DMAG and 65% of NVP-AUY922 present at 30 min post-injectionwere retained in the retina 6 h post-dose.
For 17-AAG and ganetespib, retinal elimination was rapid (90% and 70% of drugs eliminated from the retina at
6 h, respectively) which correlated with lower R/P ratios. These ﬁndings indicate that prolonged inhibition of
Hsp90 activity in the eye results in photoreceptor cell death.Moreover, the results suggest that the retina/plasma
exposure ratio and retinal elimination rate proﬁles of Hsp90 inhibitors, irrespective of their chemical class,
may predict for ocular toxicity potential.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Heat shock protein 90 (Hsp90) is a ubiquitously expressedmolecular
chaperone required for the post-translational stability of its target
substrates, known as client proteins, many of which are critical for cell
growth, differentiation and survival (Taipale et al., 2010). In addition to
playing an indispensable role in the normal homeostatic maintenance
of organs and tissues, it is now recognized that the chaperone functions
of Hsp90 can become subverted during tumorigenesis (Whitesell and
Lindquist, 2005). In this setting Hsp90 can serve as a biochemical buffer
to promote the structural and functional stability of a number of onco-
genic signaling proteins causally implicated in human cancers (Trepel
et al., 2010; Whitesell and Lindquist, 2005). Of note, pharmacologic
inhibition of Hsp90 results in destabilization and targeted proteasomal
destruction of these clients and a unique feature of Hsp90 blockade. Open access under CC BY-NC-ND liceis that it provides a means to simultaneously inhibit multiple oncogenic
pathways. For these reasons, Hsp90 has emerged as an attractive molec-
ular target for the development of novel cancer therapeutics (Banerji,
2009; Kim et al., 2009).
Ocular toxicities are a common side-effect of systemic chemothera-
peutic drugs (al-Tweigeri et al., 1996) and have also emerged as an im-
portant clinical concern for newer molecularly-targeted agents entering
standard oncology practice (Renouf et al., 2012). Theﬁrst class of targeted
Hsp90 compounds characterized was the benzoquinone ansamycins,
which include the natural product geldanamycin and its derivatives
17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin)
and 17-AAG (17-allylamino-17-demethoxygeldanamycin) (Taldone
et al., 2008). In recent years, an increasing number of synthetic small
molecule inhibitors of Hsp90 have also been developed that are based
on a diverse variety of chemical scaffolds, including resorcinol, purine
and benzamide structures (Biamonte et al., 2010; Taldone et al.,
2008). In human clinical trials some Hsp90 inhibitors, including 17-
DMAG, have been associated with visual disorders including blurred
vision, ﬂashes, delayed light/dark accommodation, night blindness
and photophobia (Kummar et al., 2010; Pacey et al., 2011; Samuel
et al., 2010; Shapiro et al., 2010). These ocular adverse effects are
often reversible though dose-limiting; moreover, the clinical evaluationnse.
402 D. Zhou et al. / Toxicology and Applied Pharmacology 273 (2013) 401–409of the second-generation aminobenzamide-based inhibitor, PF-04929113
(SNX-5422), was recently discontinued by Pﬁzer based on signiﬁcant
drug-related ocular toxicity in both preclinical and clinical studies
(Rajan et al., 2011). The molecular mechanisms underlying such visual
disturbances remain undeﬁned, although recent animal toxicology stud-
ies have suggested that retinal dysfunction linked to photoreceptor de-
generation and cell deathmaybe a contributing factor (Rajan et al., 2011).
Interestingly, a number of other Hsp90 inhibitors that have under-
gone clinical evaluation, including 17-AAG and ganetespib (a second
generation resorcinolic compound), have not manifested the same de-
gree of visual abnormalities seen for these other compounds (Banerji
et al., 2005; Cho et al., 2011; Demetri et al., 2011; Goldman et al.,
2010; Ramalingam et al., 2008; Ramanathan et al., 2005, 2007; Solit
et al., 2007;Wong et al., 2011). The reasons for the superior ocular safe-
ty proﬁle exhibited by 17-AAG and ganetespib are presently unknown.
Here, histopathological changes and retinal drug distribution proﬁles
of four Hsp90 inhibitors, with or without reported clinical visual distur-
bances, were evaluated in a rodent model in order to understand the
observed differences in ocular toxicity proﬁle among agents in this
class. A characteristic feature of targeted Hsp90 inhibition is the induc-
tion of heat shock protein 70 (Hsp70), a related molecular chaperone
that plays a key role in the chaperone complex machinery (Mayer and
Bukau, 2005). In this regard, Hsp70 upregulation is a commonly used
surrogate biomarker for Hsp90 blockade (Whitesell et al., 2003) and
was used as a biological readout for Hsp90 inhibition in the rat retina.
Results presented in this report suggest that Hsp90 plays a critical
role in normal retinal function and suggest that aberrant inhibition of
Hsp90 activity in the eye results in structural damage of the retina and
photoreceptor cell death. In addition, the data suggest that the retina/
plasma exposure ratio and retinal elimination rate proﬁles of individual
Hsp90 inhibitor compounds, irrespective of their chemical class, repre-
sent predictive factors for assessing compounds' potential for ocular
damage.
Materials and methods
Hsp90 inhibitors. 17-DMAG and 17-AAGwere purchased from LC Labora-
tories (Woburn, MA) and NVP-AUY922 from Selleck Chemicals (Houston,
TX). Ganetespib was synthesized by Synta Pharmaceuticals Corp.
Animals, tissue processing and immunohistochemistry. All in vivo proce-
dures were approved by the Synta Pharmaceuticals Corp. Institutional
Animal Care and Use Committee and carried out in strict accordance
with the Guide for Care and Use of Laboratory Animals of the National
Institutes of Health. Male Sprague Dawley (SD) and Long Evans
rats (220 ± 60 g; Charles River Laboratories, Wilmington, MA) were
maintained on a 12 h light–dark cycle. Rats were dosed with either
17-DMAG (20 mg/kg), 17-AAG (80 mg/kg), ganetespib (20 mg/kg),
NVP-AUY922 (10 mg/kg) or vehicle (17-DMAG was formulated in
D5W [5% dextrose in water] and the other three compounds in DRD
[10% DMSO/14% Cremophor RH40/76%D5W]). All four inhibitors were
dosed intravenously as this represents the clinical route of administra-
tion for each. Animals were treated on a 2 consecutive day dosing
schedule. Eyeswere harvested 24 h after the last dose, ﬁxed inModiﬁed
Davidson's solution for 24–48 h, and then washed with 70–90% etha-
nol. Parafﬁn-embedded eye sections (5 μm) were subject to routine
H&E staining, TUNEL staining using the ApopTag Peroxidase ISOL
Apoptosis Detection kit (Millipore, Billerica, MA), or immunohisto-
chemistry with a rabbit polyclonal antibody directed against Hsp70
(1:100 dilution; #4872, Cell Signaling Technology, Danvers, MA),
according to manufacturers' protocols. Negative control staining was
performed in the absence of primary antibody.
Histological assessment. Histology slides were reviewed in a blind
fashion by two independent investigators followed by a board certiﬁed
pathologist. TUNEL stained sections were scored semi-quantitatively asfollows: negative (−), ≤20 cells/overall section; minimal (±), 21–
50 positive cells/overall section; mild (+), N50 positive cells in less
than 30% of overall retinal section; moderate (++), N50 positive cells
in 30–60% of the overall retinal section; severe (+++), N50 positive
cells in greater than 60% of the overall retinal section. Quantitative
image analysis was performed on the Hsp70 immunostained sections.
Three prominently stained retinal regions per rat were randomly select-
ed from the peripheral area, proximal to the optical nerve, and within
the intervening region. Images were captured under identical electronic
exposure proﬁles and analyzed using Image-Pro Plus software (Media
Cybernetics Inc., Rockville, MD) at 20× magniﬁcation, and measured
as the percentage of Hsp70 positive and negative areas from the inner
segment of the photoreceptor layer to the ganglion cell layer. The
average %Hsp70-positive area/rat valueswere calculated and expressed
as a fold change (median ± SD) compared to the vehicle group. Statis-
tical signiﬁcance was set at P b 0.05 using one-way ANOVA.
Retinal morphological evaluation. As an index of photoreceptor cell
loss, a quantitative measurement of mean outer nuclear layer (ONL)
thickness was performed according to previously published procedures
(LaVail and Lawson, 1986;Williams andHowell, 1983). Ratswere treat-
ed with vehicle or 17-DMAG at 20 mg/kg/day, every other day (q.o.d.)
for 2 weeks. This dose schedule provided repeated exposure to the
inhibitor, and was identiﬁed in pilot studies as the maximally tolerated
dose. Twenty-four hours after the ﬁnal dose, eyes were enucleated,
ﬁxed inModiﬁed Davidson's solution and embedded in parafﬁn. Retinal
tissue was sectioned (4-μm thickness) along the vertical meridian
through the optic nerve and stained with H&E. In each of the superior
and inferior hemispheres, the ONL thickness was measured quantita-
tively using Image-Pro Plus software. The ONL thickness of each of the
superior and inferior hemispheres was measured in nine sets of three
measurements each (total of 27 measurements per hemisphere). Each
set was centered on adjacent 500 ± 50 μm segments of the retina, with
the ﬁrst point of measurement taken approximately 170 ± 30 μm from
the optic nerve head and subsequent sets located toward the periphery.
Comparisons of ONL thickness were made between vehicle and 17-
DMAG-treated animals using 6 rats per group.
Western blotting. Retinal tissue (including the retinal pigment epitheli-
um layer) from both eyes was dissected using previously described
methodology (Barres et al., 1988) and homogenized in a lysing matrix
tube (MP Biosciences, Santa Ana, CA) containing lysis buffer (Cell
Signaling Technology). Lysates were clariﬁed by centrifugation
and equal amounts of protein resolved by SDS-PAGE before transfer
to nitrocellulose membranes (Invitrogen, Carlsbad, CA). Membranes
were blocked and then immunoblottedwith antibodies directed against
Hsp70/72 (C92F3A-5; Enzo Life Sciences, Farmingdale, NY) or GAPDH
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA). The antibody–antigen
complex was visualized and quantitated using the Odyssey system
(LI-COR, Lincoln, NE).
Pharmacokinetic analysis. 17-DMAG (20 mg/kg), 17-AAG (80 mg/kg),
ganetespib (20 mg/kg) andNVP-AUY922 (10 mg/kg)were i.v. adminis-
tered to male SD rats (n = 3). For consistency with the experimental
protocol, animals were given two consecutive daily doses of inhib-
itor prior to PK assessment. Following retro-orbital blood collection,
plasma samples were protein precipitated and analyzed by liquid
chromatography–tandem mass spectrometry (LC–MS/MS). Noncom-
partmental pharmacokinetic analysis was performed using Phoenix
WinNonlin ver. 6.3 (Pharsight, Mountain View, CA) for individual
animals and mean data reported for the group.
For the determination of plasma and retinal tissue drug concentra-
tions, inhibitors were i.v. administered to rats (n = 3) as two consecu-
tive daily doses and plasma and retina samples were collected at 0.5, 6
and 18 h after the ﬁnal dose for bioanalysis. To do this, animals were
euthanized and retinal samples from each time point were pooled and
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homogenization in phosphate buffered salinewith an IKA homogenizer.
Blood was collected from the vena cava for plasma preparation. Plasma
and homogenized retinal samples were then extracted by protein pre-
cipitation and analyzed by LC–MS/MS. A Phenomenex Kinetex 2.6 μ
C18 (30 × 2.1 mm) column was used with a run time of 3.5 min per
sample.Statistical analysis. Data were expressed as means ± SD. Mean or
median values were analyzed using one-way ANOVA with Dunn's
Method for multiple comparisons versus the control groups. P values
less than 0.05 were considered statistically signiﬁcant.Results
Chemical structure and clinical visual disturbance proﬁle of
Hsp90 inhibitors
Four small molecule Hsp90 inhibitors, all of which exhibit competi-
tive binding for the ATP pocket at the N-terminus of Hsp90, were used
in this study and their chemical structures are presented in Fig. 1. 17-
DMAG and 17-AAG both belong to the ansamycin class. Despite their
close structural similarity, visual disturbances have been associated
with 17-DMAG, but not 17-AAG, in human clinical trials (Kummar
et al., 2010; Pacey et al., 2011). Ganetespib is a novel second genera-
tion resorcinolic triazolone compound that is structurally distinct
and more potent than the ﬁrst-generation ansamycins and does
not cause visual disturbances (Ying et al., 2012). NVP-AUY922 is
another resorcinol-based second generation inhibitor of Hsp90
(Eccles et al., 2008) and, in contrast to ganetespib, ocular toxicities
have recently emerged as an undesirable side-effect for this compound
(Samuel et al., 2010).Fig. 1. Chemical structures of the Hsp90 inhibitors 17-dimethylaminoethylamino-17-
demethoxygeldanamycin (17-DMAG), 17-allylamino-17-demethoxygeldanamycin
(17-AAG), ganetespib and NVP-AUY922. CLogP values calculated for each compound
using ChemBioDraw software (CambridgeSoft) are shown.17-DMAG induced retinal degeneration involves the photoreceptor outer
nuclear layer in rats
Histologically, the retina is composed of multiple layers of neuronal
cells. H&E staining of a normal retina from a vehicle-treated Sprague
Dawley (SD) rat revealed an orderly structural organization (Fig. 2A),
within which the ganglion cell layer (GCL), the photoreceptor inner nu-
clear layer (INL) and outer nuclear layer (ONL) (containing the rod and
cone cells) could be readily delineated. First a repeat-dose experiment
using SD rats treated with i.v. administration of 17-DMAG (20 mg/kg)
or vehicle (D5W) q.o.d. for twoweekswasperformed. This dosewasde-
termined to be themaximally tolerated dose (MTD) for the drug, above
which animalmortalitywas observed.When retinalmorphologieswere
initially examined by H&E staining no discernible differences were seen
in vehicle-treated animals; in contrast, 17-DMAG exposure resulted in
marked attenuation of the thickness of the ONL and prominent cellular
degenerative changes within this region, as evidenced by extensive
nuclear condensation and pyknosis (data not shown). These changes
suggested that photoreceptor degeneration resulted as a consequence
of exposure to the Hsp90 inhibitor. Therefore the mean ONL thickness
in vehicle- and 17-DMAG-treated SD rats was examined as a measure
to evaluate the degree of photoreceptor cell loss. The ONL thickness
was measured along the entire vertical meridian, and the mean thick-
ness values (n = 6 rats) are plotted in Fig. 2B. Compared to the vehicle
control rats, the mean ONL thickness in 17-DMAG treated animals
was markedly reduced along the entire length of the retina; by 20–
37% within the inferior hemisphere and by 20–62% within the superior
hemisphere.Within themore sensitive superior hemisphere, the reduc-
tions in thickness were greatest toward the periphery compared to the
more central regions (Fig. 2B).
Fig. 2C (upper panel) shows representative H&E images of retinas
obtained from vehicle and 17-DMAG treated SD rats, corresponding
to segment 9 of the superior hemisphere shown in Fig. 2B. The loss of
ONL thickness was readily apparent (reduced from approximately
9–10 rows of nuclei to 3–4 following 17-DMAG treatment), as was a
major disorganization and substantial loss of photoreceptor inner and
outer segment membranes. TUNEL staining of adjacent tissue sections
(Fig. 2C, lower panel) revealed the presence of apoptotic cells, conﬁned
to the ONL, consistent with a model of selective photoreceptor cell
loss occurring in response to 17-DMAG exposure.
In subsequent experiments, rats were treated with vehicle or
20 mg/kg 17-DMAG for two consecutive days and retinas harvested
24 h following the last dosing. TUNEL staining conﬁrmed that the cellu-
lar damage occurring within the ONL was due to apoptotic loss of pho-
toreceptors (Fig. 2D, upper panel). Because SD rats lack a pigmented
epithelial cell layer, we performed a comparative study using Long
Evans rats to determine whether the presence of this layer conferred
any protection from Hsp90 inhibitor-induced cytotoxicity. As shown
in Fig. 2D (lower panel), 17-DMAG exposure also resulted in extensive
apoptotic induction throughout, and restricted to, the ONL in these
animals. The structural damage and widespread cell death observed
within the retinal photoreceptor layer underscore the ocular toxicity
seen in rats treated with 17-DMAG.
Up-regulation of the inducible heat shock protein 70 (Hsp70) following
17-DMAG exposure accompanies apoptotic induction
Hsp90 is ubiquitously observed throughout all layers of the retina
(Dean and Tytell, 2001) and no signiﬁcant changes in total protein
levels were seen by Western blot following 17-DMAG treatment
(Supplementary Fig. 1). Therefore levels of the stress protein Hsp70
were examined as a surrogate marker for Hsp90 inhibition, since
Hsp70 expression is induced following treatmentwithHsp90 inhibitors
(Whitesell et al., 2003). As shown in Fig. 3A, Hsp70 was robustly up-
regulated following 17-DMAG treatment, displaying strong cytoplasmic
staining in the inner segment and synaptic regions of the photoreceptor
Fig. 2. 17-DMAG-induced ocular toxicity involves apoptotic cell death within the photoreceptor outer nuclear layer (ONL) in both Sprague Dawley (SD, albino) and Long Evans
(LE, pigmented) rats. (A) H&E staining of a normal retina from a vehicle (D5W)-treated SD rat shows an orderly arrangement of photoreceptors, including the outer nuclear layer
(ONL), inner nuclear layer (INL) and ganglion cell layer (GCL). Scale bar, 50 μm. (B) Loss of ONL thickness across the retina following 17-DMAG treatment. SD rats were treated with
repeated doses of vehicle (openboxes) or 20 mg/kg17-DMAGq.o.d. (closed boxes) for twoweeks and eyes harvested 24 h after theﬁnal dose. TheONL thicknesswithin eachof the superior
and inferior hemispheres was measured in nine sets of adjacent 500 ± 50 μm segments from the optic nerve (ON). Each data point represents the mean ± SD obtained from 6 rats.
(C) Representative tissue sections taken from point 9 in the superior hemisphere as shown in (B). H&E staining is shown in the upper panel and TUNEL staining in the lower. Scale bar,
50 μm. (D) TUNEL staining of retinal tissue harvested from SD (upper panels) and LE (lower panels) rats 24 h after 2 consecutive daily doses of 20 mg/kg 17-DMAG conﬁrms the presence
of apoptotic photoreceptors within the ONL. Insets show apoptotic cells in more detail. Original magniﬁcation, 100×. Scale bar, 50 μm.
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layers — a distribution consistent with targeted Hsp90 inhibition
occurring selectively within the cells of this region. Next the kinet-
ics of Hsp70 regulation were determined by Western blot (Fig. 3B).
Hsp70 protein levels were maximally induced 24 h following the
last 17-DMAG treatment (Day 1), remained elevated for at least
3 days, and then returned toward the baseline level at Day 5. This
temporal induction of Hsp70 was conﬁrmed by immunostaining
(Fig. 3C, upper panel). Interestingly, when concomitant TUNEL
staining was performed we observed almost identical kinetics
of apoptotic induction (Fig. 3C, lower panel). The relative levels
of Hsp70 protein expression are quantitated in Fig. 3D and apopto-
tic scores shown in Fig. 3E. Taken together, these data show that
17-DMAG treatment aberrantly inhibits Hsp90 activity in retinal
photoreceptor cells and this exposure promotes subsequent cell
death.Comparison of retinal degeneration in SD rats treated with the Hsp90
inhibitors 17-AAG, ganetespib and NVP-AUY922
Retinal damage proﬁles of 17-AAG, ganetespib and NVP-AUY922
were examined. Rats were treated with 2-day consecutive dosing
of vehicle (DRD), 17-AAG (80 mg/kg), ganetespib (20 mg/kg) or NVP-
AUY922 (10 mg/kg) before retinal harvest 24 h later. The 17-AAG
dose used was the maximally tolerated dose (MTD) for this drug in
order to provide a direct comparison with 17-DMAG in the rat model
system. Continuing development of these two ansamycin Hsp90 inhib-
itors as cancer therapeutics has largely been halted; however both
of the second-generation compounds ganetespib and NVP-AUY922
are currently undergoing clinical evaluation inmultiple trials and cancer
types. Therefore the doses of ganetespib and NVP-AUY922 used in
this study were selected based on equivalency to clinically-relevant
human dosing levels. Similar to what was observed for 17-DMAG,
Fig. 3.Hsp70 expression is up-regulated following 17-DMAG exposure and accompanies apoptotic induction. SD rats were treatedwith 2 consecutive daily doses of vehicle (D5W) or 17-
DMAGand retinas harvested after 1, 3 and 5 days. (A) Representative image of Hsp70 immunoreactivity in the SD rat retina following exposure to 17-DMAG. Scale bar, 50 μm. (B) Kinetics
of Hsp70 protein regulation after 17-DMAG treatment assessed byWestern blot. Each lane represents retinal tissue from an individual animal. Hsp70 expression was maximally induced
1 day following the last dose, remained elevated at Day 3, and then returned to baseline levels at Day 5. GAPDH included as a loading control. (C) Time course of Hsp70 (upper panel) and
apoptosis (lower panel) induction determined by immunohistochemistry and TUNEL staining, respectively. Maximal expression of both Hsp70 and apoptotic photoreceptor destruction
was seen 1 day following the last 17-DMAG dosing. Scale bars, 50 μm. (D) Quantiﬁcation of Hsp70 expression for Days 1, 3 and 5. *P b 0.05; one-way ANOVA. (E) Quantiﬁcation of the
apoptotic index (average histology scores) for Days 1, 3 and 5. *P b 0.05.
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In stark contrast, and consistent with an absence of clinically reported
visual changes, neither 17-AAG nor ganetespib produced any detectable
apoptotic photoreceptor injury (Fig. 4A, Table 1). As predicted by these
ﬁndings, only NVP-AUY922 treatment elicited robust up-regulation
of Hsp70 within the retinal tissue (Fig. 4B).Fig. 4.Retinal toxicity proﬁles of 17-AAG, ganetespib andNVP-AUY922. (A) TUNEL staining of SD
or AUY922. Inset shows apoptotic induction within the ONL in response to NVP-AUY922 expos
Western blot from 3 individual animals following Hsp90 inhibitor treatment. GAPDH includedComparative pharmacokinetics
The relationship between drug distribution proﬁles and photorecep-
tor degeneration using pharmacokinetic (PK) analyses was examined
for each Hsp90 inhibitor. The plasma concentration–time proﬁles
presented in Fig. 5A were obtained after the i.v. administration of eachrat retinal tissue 24 h after 2 consecutive daily doses of vehicle (DRD), 17-AAG, ganetespib
ure in more detail. Scale bar, 50 μm. (B) Retinal Hsp70 protein expression determined by
as a loading control.
Table 1
Comparison of Hsp90 inhibitor ocular toxicity in SD rats.
Compound Dosage
(mg/kg/day ×2, i.v.)
IHC staining Western blot
Apoptosisa
(# affected/total animals) (scoreb)
Hsp70 increase vs. controla (% ± SD)
Vehicle 0 19/20 (−), 1/20 (±) 0 ± 9
17-AAG 80 0/7 (−) 14 ± 7
Ganetespib 20 0/7 (−) 34 ± 12
17-DMAG 20 9/9 (+)–(+++) 122 ± 24⁎
NVP-AUY922 10 6/6 (±)–(+++) 117 ± 7⁎
a Evaluations performed 24 h following ﬁnal dose.
b Histological score for apoptosis (TUNEL staining): (−) negative, (±) minimal, (+) mild, (++) moderate, and (+++) severe.
⁎ P b 0.05. Multiple comparisons versus control group (Dunn's Method).
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summarized in Table 2. Collectively the data show that inhibitor differ-
ences in standard PK parameters did not correlate with the capacity
to induce retinal effects. Notably, the peak concentrations of 17-DMAG
and NVP-AUY922, both of which were retinal damage inducers, were
substantially lower than those for 17-AAG and ganetespib (Table 2).
Indeed, ganetespib showed an almost 25-fold higher Cmax value than
17-DMAG when administered at the same 20 mg/kg dose (Fig. 5A)
and, over time, was present at higher circulating concentrations than
NVP-AUY922. Reﬂecting its dosing level (80 mg/kg), 17-AAG showed
the highest initial plasma drug concentrations however the short half-
life of the compound (T1/2, 2.8 h) promoted rapid clearance from
the bloodstream (Fig. 5A). Because the extent of plasma protein bindingFig. 5.Comparative pharmacokinetic analyses. (A)Meanplasma concentration–time proﬁles aft
NVP-AUY922 were dosed at 20 mg/kg, 80 mg/kg, 20 mg/kg and 10 mg/kg, respectively. Data re
istration of Hsp90 inhibitors to SD rats. Retinal samples were collected at 0.5, 6 and 18 h post-
retina/plasma (R/P) drug concentration ratios and (D) retinal elimination rates over time. Plas
kinetic analysis. Data are presented from pooled samples representing 3 animals/time point. Th
NVP-AUY922 and 17-DMAG,whichproduced severe ocular effects, displayed thehighest R/P rat
retinal damage. Retinal elimination proﬁles correlatedwith the degree of observed toxicity. 17-A
rapidly eliminated from the retina compared to 17-DMAG and NVP-AUY922.can inﬂuence the activity of a drug we additionally determined
the unbound fraction of each compound, listed in Table 2. Interestingly,
despite their different potentials for retinal degeneration, the two
resorcinolic compounds showed almost identicalmean unbound plasma
fraction values (2.4% and 2.5% for NVP-AUY922 and ganetespib, respec-
tively) suggesting that the availability of these two potent inhibitory
agents for on-target Hsp90 effects was comparable.
Retina/plasma exposure ratio and retinal elimination rate are linked to
photoreceptor toxicity induced by Hsp90 inhibitors
A comprehensive evaluation of the SD rat tissue distribution proﬁles
for each Hsp90 inhibitor measured at 0.5, 6 and 18 h post-dosing iser the i.v. administration of Hsp90 inhibitors to SD rats. 17-DMAG, 17-AAG, ganetespib and
present mean ± SD (n = 3). (B) Retinal concentration–time proﬁles after the i.v. admin-
dose. Data are presented on a logarithmic base 2 scale. (C) Comparison of Hsp90 inhibitor
ma and retinal samples were collected at 0.5 and 6 h post-dose and subject to pharmaco-
e bar graph inset in panel (C) denotes the relative R/P ratios at the initial 0.5 h time point.
ioswhereas the lowerR/P ratios of ganetespib and 17-AAGwere associatedwith less risk of
AG and ganetespib, both ofwhich showed an absence of adverse ocular effects, weremore
Table 2
Pharmacokinetics of selected Hsp90 inhibitors in SD rats.
Compound 17-AAG 17-DMAG Ganetespib NVP-AUY922
Dose (mg/kg/day ×2) 80 20 20 10
T1/2 (h) 2.8 NR 6.4 5.6
Tmax (h) 0.083 0.083 0.083 0.083
Cmax (μM) 487 4.48 110 6.19
AUCt (μM·h) 619 7.43 36.1 2.63
Mean unbound
plasma fractiona (%Fu)
5.0 16.0 2.5 2.4
NR, not reportable due to insufﬁcient characterization of the terminal phase.
a Concentration tested 10 μM.
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of each compound were found to be generally higher in the retina than
in the plasma, conﬁrming the ability of each compound to penetrate
the blood–retina barrier, however the overall plasma concentration
alone did not predict for retinal exposure. When retinal concentrations
were plotted as a function of time (Fig. 5B) it was found that treatment
with the two second generation compounds resulted in comparable
levels of drug at the 0.5 h time point, yet the retinotoxic NVP-AUY922
displayed higher sustained concentrations up to 18 h compared to
ganetespib. Similarly, while dosing the ansamycin inhibitors at their
respective MTDs resulted in greater overall retinal values initially, 17-
DMAG showed comparatively higher tissue retention than 17-AAG
over time (Fig. 5B). In order to more directly compare the distribution
proﬁles, we determined the retina/plasma (R/P) drug concentration
ratio for each compound (Table 3, Fig. 5C), and this parameter was
found to directly relate to the photoreceptor cell death observed above.
17-DMAGandNVP-AUY922, both ofwhich showed severe ocular effects,
had R/P ratios at 0.5 h of 6.8 and 4.5, respectively, whereas 17-AAG (R/P
ratio of 0.14) and ganetespib (R/P ratio of 1.1) had much lower values
(Fig. 5C, Table 3). The higher R/P ratios for NVP-AUY922 and 17-DMAG
indicated that these compounds distributed more readily to the retina.
Further, at the 6 h time point, the R/P ratios for 17-DMAG and NVP-
AUY922 remained greater than those of 17-AAG and ganetespib (51
and 288 vs. 1.8 and 28.9, respectively). Moreover, these accumulation
proﬁles were directly associated with the retinal elimination rate
(Fig. 5D), as suggested by Fig. 5B. For 17-AAG, retinal elimination was
rapid — at 6 h post-dose, 90% of 17-AAG present at 30 min had been
eliminated from the retina, accounting for the low R/P ratio. Ganetespib
exhibited a similar proﬁle, with 70% retinal elimination of the drug
over the same time period. Both 17-DMAG and NVP-AUY922 showed
substantially slower rates of elimination from the retina at 6 h (Fig. 5D,
Table 3). Even at 18 h, NVP-AUY922 showed only 43% clearance com-
pared to 87% for ganetespib. Taken together, these data suggest that
both the degree and duration of Hsp90 inhibitor drug exposure in the
retina are linked to ocular toxicity potential.Table 3
Summary of plasma and retinal drug concentrations following Hsp90 inhibitor treatment.
Hsp90 inhibitor Dose
(mg/kg)
Time
(h)
Plasma
(μM)
Retina
(nmol/g)
R/P ratioa Retinal
elimination
17-AAG 80 0.5 444 59.8 0.14 –
6 3.36 6.18 1.8 90%
18 0.52 1.47 2.8 98%
Ganetespib 20 0.5 7.29 7.79 1.1 –
6 0.08 2.30 28.9 70%
18 0.005 0.99 190 87%
17-DMAG 20 0.5 4.71 32 6.8 –
6 0.32 16.2 51 49%
18 0.29 8.64 30 73%
NVP-AUY922 10 0.5 1.33 5.91 4.5 –
6 0.013 3.85 288 35%
18 0.004 3.36 752 43%
a Assuming 1 g tissue equivalent to 1 mL.Discussion
The advent of molecularly targeted therapies has ushered in a new
era for cancer treatment. While these agents are generally considered
to be more tumor-selective and hence elicit fewer side effects than tra-
ditional chemotherapeutic drugs, toxicities in normal tissues and organs
are still commonly observed. Because of their relatively small mass and
rich vascular supply, the eyes are particularly susceptible to insult from
systemically administered cytotoxic agents (Peponis et al., 2010). In
addition, their high metabolic rate and inability to regenerate following
damage are also causative factors. Exposure to toxic compounds can
modify the physiology of retinal neurons and this in turn can lead
to major, and in some cases irreversible, visual sensory loss (Renouf
et al., 2012). To date, the pathogenic mechanisms of many retinotoxic
drugs have not been well characterized although it is reasonable to
suggest that on-target effects resulting from suppression of oncogenic
targets and signaling pathways, which also exist within ocular tissues,
play a signiﬁcant role.
In this study, we initially evaluated histopathological changes
induced within the retina by four Hsp90 inhibitors, two from the
prototypical ansamycin class (17-DMAG and 17-AAG) and two second-
generation resorcinolic compounds (ganetespib and NVP-AUY922).
Although not included in the present report, ocular adverse events
have not been noted in clinical trials of the purine scaffold-based syn-
thetic Hsp90 inhibitor, BIIB021 (Dickson et al., 2013; Elﬁky et al., 2008).
Consistent with their clinical visual symptom proﬁles, 17-DMAG and
NVP-AUY922 each inducedmarked photoreceptor cell death, but similar
effects were not produced by either 17-AAG or ganetespib treatment.
Interestingly, the morphologic and structural changes observed in the
rat retina (degeneration of the photoreceptor segments and thinning
of the ONL) are similar to what has been seen following retinal photic
injury (Shahinfar et al., 1991; Youssef et al., 2011), suggesting that phar-
macological insult and light damage may manifest similar pathologic
outcomes in this tissue.Moreover, the identical retinal damage produced
by two structurally distinct Hsp90 inhibitors (17-DMAG and NVP-
AUY922) provides further evidence that retinal toxicity induced by this
group of agents is a drug target-dependent process.
In rat ocular tissue, Hsp90 is abundantly expressed within the retina
(Dean and Tytell, 2001) suggesting that its chaperoning activities play
essential roles in normal photoreceptor function. Our ﬁndings indicate
that prolonged or aberrant inhibition of Hsp90 activity in the retina
results in photoreceptor death. Hsp90 controls the folding of numerous
key signaling molecules required to maintain normal cell function,
including ubiquitously expressed apoptotic regulators such as AKT and
its effector molecule glycogen synthase kinase 3 (Sato et al., 2000).
Therefore, blockade of pro-survival signals could readily account for
the rapid onset of apoptotic loss observed following sustained 17-
DMAGorNVP-AUY922 exposure. In addition, thehigh degree of special-
ization exhibited by photoreceptor cells predicts for unique chaperone
requirements (Kosmaoglou et al., 2008). In this regard, photoreceptor
cell-type speciﬁc Hsp90 client proteins may represent critical targets
whose function is may be profoundly impacted by Hsp90 inhibition.
For example, aryl hydrocarbon receptor interacting protein-like 1
(AIPL1) is expressed by cone and rod photoreceptor cells and plays a
critical role in cellular viability (Kirschman et al., 2010). Mutations
in this gene underlie one of the most severe forms of inherited retinal
dystrophy, Leber Congenital Amaurosis (LCA) (den Hollander et al.,
2008; Sohocki et al., 2000). Notably, AIPL1 has been shown to interact
with Hsp90 (Hidalgo-de-Quintana et al., 2008) and is thought to repre-
sent a retina-speciﬁc co-chaperone that is required for the assembly
of essential photoreceptor enzymes including the phototransduction
protein, phosphodiesterase (Kirschman et al., 2010; Kosmaoglou et al.,
2008). Studies investigating the precise client proteins and signal cas-
cades that are destabilized following inhibition of Hsp90 in this tissue
are underway. It is also interesting to note that, despitemultiple reports
of Hsp90 inhibitors inducing cytotoxic effects in cultured retinal
408 D. Zhou et al. / Toxicology and Applied Pharmacology 273 (2013) 401–409pigment epithelium (RPE) cells in vitro (Kaarniranta et al., 2005;
Wu et al., 2010; Yao et al., 2010), only low endogenous levels of
Hsp90 protein are found in these cells in situ (Dean and Tytell, 2001)
and we observed no apoptotic changes in the SD rat RPE following
Hsp90 inhibitor treatment.
Importantly, this study provides the ﬁrst evidence of a mechanistic
basis for different ocular toxicity potentials exhibited by small molecule
inhibitors of Hsp90. The similar toxicity proﬁles and biological re-
sponses elicited by 17-DMAG and NVP-AUY922 indicated that it was
not simply chemical class that dictated the capacity to induce retinal
degeneration. Indeed the lack of retinal damage seen with 17-AAG
and ganetespib, also in accordance with their clinical safety proﬁles,
supported this premise. Among the compounds studied, 17-DMAG
and NVP-AUY922 contain salt-forming amine groups and are more hy-
drophilic than either 17-AAG or ganetespib, though it is unlikely that
this pharmaceutical property alone is sufﬁcient to account for the differ-
ent toxicities seen within this group of therapeutic agents. Instead,
our pharmacokinetic examination of the relationship between retinal
drug distribution proﬁles and photoreceptor degeneration showed
that the retention characteristics of each agent appeared to be a predic-
tive factor for retinal damage. All four compounds showed distribution
into the retinal tissue; however the potential for photoreceptor damage
was related to the two interconnected parameters of retina/plasma
ratio and retinal elimination rate. Indeed, the higher initial R/P ratios
for 17-DMAG and NVP-AUY922 indicated that both compounds distrib-
uted more readily to the retinal compartment compared to the non-
retinotoxic inhibitors and actual drug concentrations of each were
sustained at higher levels over time. In addition, these characteristics
were sufﬁcient to account for the robust upregulation of Hsp70 seen 1
to 3 days following17-DMAGexposure. Hsp70 induction,while a useful
marker of Hsp90 inhibition, also reﬂects the activation of an evolution-
arily conserved cellular stress response wherein this chaperone may
exert cytoprotective activity and play a central role in the triage of
damaged proteins following proteotoxic stress (Lanneau et al., 2010).
Overall, while all inhibitors successfully penetrated the blood–retina
barrier, the degree and duration of retinal exposure differed even
among compounds of the same class, and it was these characteris-
tics that determined the extent of photoreceptor injury.
Studies of ocular drug reactions are best performed in species for
which the information can be most relevantly applied to the clinical
setting. The SD rat is commonly used for regulatory toxicity testing
and the retinotoxic responses to individual Hsp90 inhibitors observed
in this strain reﬂected the safety proﬁles seen in patients. However
since these albino animals lack melanin in the RPE or the uveal tract,
an important consideration for this study was whether pigmentation
of the eye could affect the outcome of Hsp90 inhibitor exposure, given
that a large number of structurally and pharmacologically unrelated
drugs show signiﬁcant afﬁnity for binding to melanin. In this regard,
while drug binding to melanin itself is not predictive of retinal toxicity
(Leblanc et al., 1998), the presence of this biological pigment may
impact local drug concentrations by promoting accumulation within
the retinal compartment. As shown in Fig. 2, the pigmented LE rat strain
remained susceptible to 17-DMAG-induced retinal damage — which
was similarly restricted to the photoreceptor layer. Moreover, addition-
al tissue distribution studies performed in LE rats also demonstrated
higher R/P ratios for the retinotoxic 17-DMAG and NVP-AUY922 inhib-
itors compared to ganetespib and 17-AAG (D. Zhou, unpublished obser-
vations). These data are consistent with the observations found in the
SD rat and suggest that the presence of melanin in the pigment epithe-
lium unlikely plays a major role in determining the relative retention
kinetics of these four compounds within the rat eye.
Finally, our ﬁndings validate the use of a rodentmodel to assess risks
of visual disturbances and retinal dysfunction induced by targeted
Hsp90 inhibition. Evaluation of retinal pathology, heat shock protein
modulation and proﬁles of retinal drug exposure in rats represented
a relatively straightforward, sensitive and robust approach to detectretinal cell death within 24 h after drug administration. This metho-
dology provides a practical advantage over more sophisticated experi-
mental approaches, such as electroretinography (ERG), which requires
specialized equipment to assess clinical visual changes that take consid-
erably longer times tomanifest andmonitor. Perhapsmost signiﬁcantly,
our results correlated with the adverse event proﬁle in humans for each
of the agents examined, and suggest that this strategy may predict the
potential for retinal damage when applied to pre-clinical screening of
candidate Hsp90 inhibitor compounds. Despite some species-related
differences (e.g. types and density of cone cells) rat and human eyes
share the same basic structure and function and rodent models have
traditionally proven useful for the investigation of ocular disease patho-
genesis, response to therapies, and toxicology screening. It is important
to note, however, that many of the visual disorders seen in patients
are reversible — therefore the photoreceptor death observed in the rat
retina likely does not account for all pathological processes occurring
in the human eye as a consequence of aberrant Hsp90 inhibition.
In summary, Hsp90 client proteins play important roles in normal
retinal function andprolongedHsp90 inhibition can lead to vision disor-
ders such as those that have been seen in the clinical setting. Our ﬁnd-
ings reveal that the drug retina/plasma exposure ratio and elimination
rate proﬁles play crucial roles in ocular toxicity and may be used as
indicators of Hsp90 inhibitor-induced damage in rats. Importantly, the
retinotoxicity potential of each of the Hsp90 inhibitors deﬁned in the
rodentmodelwas entirely consistentwith their observed clinical proﬁle
in humans. Based on these ﬁndings, it appears that adverse ocular
effects may be successfully minimized by administration of Hsp90
inhibitors with favorable drug properties that include, although are
not necessarily limited to, lower retina/plasma exposure ratios and
faster retinal elimination. In addition, improved understanding of path-
ological mechanisms that result in retinal damage will have important
implications for appropriate monitoring protocols designed to prevent
visual impairment as a result of targeted Hsp90 therapies.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.taap.2013.09.018.
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